iifl-logo-icon 1

Concord Biotech Ltd Share Price

1,686.8
(-0.55%)
Jul 19, 2024|09:44:52 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open1,706.2
  • Day's High1,706.2
  • 52 Wk High1,799
  • Prev. Close1,696.2
  • Day's Low1,665.65
  • 52 Wk Low900.05
  • Turnover (lac)110.09
  • P/E60.34
  • Face Value1
  • Book Value145.8
  • EPS28.13
  • Mkt. Cap (Cr.)17,646.66
  • Div. Yield0.52
No Records Found

Concord Biotech Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

1,706.2

Prev. Close

1,696.2

Turnover(Lac.)

110.09

Day's High

1,706.2

Day's Low

1,665.65

52 Week's High

1,799

52 Week's Low

900.05

Book Value

145.8

Face Value

1

Mkt Cap (₹ Cr.)

17,646.66

P/E

60.34

EPS

28.13

Divi. Yield

0.52

Concord Biotech Ltd Corporate Action

15 May 2024

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

23 May 2024

12:00 AM

Dividend

Dividend Amount: 8.75

Record Date: 22 Jun, 2024

arrow

23 May 2024

12:00 AM

AGM

Announcement Date: 23 May, 2024

arrow

14 Jun 2024

12:00 AM

BookCloser

arrow

Concord Biotech Ltd NEWS AND UPDATE

No data found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Concord Biotech Ltd SHAREHOLDING SNAPSHOT

19 Jul, 2024|05:13 PM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 44.08%

Foreign: 0.00%

Indian: 44.08%

Non-Promoter- 17.51%

Institutions: 17.51%

Non-Institutions: 38.40%

Custodian: 0.00%

Share Price

Concord Biotech Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Loading...
Y/e 31 Mar( In .Cr)Mar-2024Mar-2023Mar-2022Mar-2021

Equity Capital

10.46

10.46

9.51

9.51

Preference Capital

0

0

0

0

Reserves

1,514.79

1,281.52

1,097.65

990.16

Net Worth

1,525.25

1,291.98

1,107.16

999.67

Minority Interest

View Balance Sheet
Loading...

No Record found

View Profit & Loss
Loading...

No Record found

View Cash Flow
Loading...

No Record found

View Ratios
Particulars (Rupees in Crores.)Mar-2024Mar-2023Mar-2022Mar-2021

Gross Sales

1,016.94

853.17

712.93

616.94

Excise Duty

0

0

0

0

Net Sales

1,016.94

853.17

712.93

616.94

Other Operating Income

0

0

0

0

Other Income

37.15

37.27

23.42

13.81

Concord Biotech Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,594.25

125.293,82,370.02867.60.855,536.9998.75

Divis Laboratories Ltd

DIVISLAB

4,584.8

77.221,21,645.675310.652,259507.93

Cipla Ltd

CIPLA

1,506.65

32.741,21,616.251,038.40.563,444.92346.41

Zydus Lifesciences Ltd

ZYDUSLIFE

1,185.65

34.71,19,268.911,405.20.253,172.6156.19

Dr Reddys Laboratories Ltd

DRREDDY

6,667.5

25.951,11,193.661,034.80.65,081.81,458.96

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Concord Biotech Ltd

Management

Register Office

Registrar Office

Chairman & Managing Director

SUDHIR JAIRAM VAID

Joint Managing Director & CEO

ANKUR VAID

Non Executive Director

Ravi Kapoor

Nominee

Rajiv Agarwal

Independent Director

BHARTI KHANNA

Independent Director

Amitabh Thakore

Independent Director

Arvind Agarwal

Independent Director

Jayaram Easwaran

Independent Director

Mandayam Chakravarthy Sriraman

Assistant VP (Finance) & CS

S Prakash

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Concord Biotech Ltd was originally incorporated as Servomed Pharmaceuticals Private Limited at Ahmedabad, Gujarat as a Private Limited Company dated November 23, 1984, issued by the Registrar of Companies. Thereafter, name of the Company was changed to Concord Biotech Limited dated February 16, 2001, which became a Public Company and a fresh Certificate of Incorporation dated November 7, 2001 was issued by the RoC.The Company is an India-based biopharma and one of the leading global developers and manufacturers of select fermentation-based APIs across immuno-suppressants and oncology in terms of market share, based on volume in supplying to over 70 countries including regulated markets, such as the United States, Europe and Japan, and India. Presently, it is engaged in research and development, manufacturing, marketing and selling of pharmaceutical products. Its API manufacturing facilities are located at Dholka and Limbasi, and formulations facility at Valthera in Gujarat.In 2000, the Company was acquired by the Promoter, Mr. Sudhir Vaid. In 2016, the Company launched formulation business in India as well as emerging markets, including Nepal, Mexico, Indonesia, Thailand, Ecuador, Kenya, Singapore and Paraguay, and have further expanded to the United States. It established a facility at Valthera, Gujarat.It set up a joint venture in Japan to grow business in 2018.In 2019, the Company received two ANDA approvals. It expanded their business into critical care segment in India.
Read More

Company FAQs

What is the Concord Biotech Ltd share price today?

Down Arrow

The Concord Biotech Ltd shares price on N/A is Rs.₹1684.05 today.

What is the Market Cap of Concord Biotech Ltd?

Down Arrow

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Concord Biotech Ltd is ₹17617.89 Cr. as of 19 Jul ‘24

What is the PE and PB ratio of Concord Biotech Ltd?

Down Arrow

The PE and PB ratios of Concord Biotech Ltd is 60.34 and 11.64 as of 19 Jul ‘24

What is the 52 Week High and Low of Concord Biotech Ltd?

Down Arrow

The 52-week high/low is the highest and lowest price at which a Concord Biotech Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Concord Biotech Ltd is ₹900 and ₹1793.5 as of 19 Jul ‘24

What is the CAGR of Concord Biotech Ltd?

Down Arrow

Concord Biotech Ltd's CAGR for 5 Years at N/I%, 3 Years at N/I%, 1 Year at 80.21%, 6 Month at 24.14%, 3 Month at 7.52% and 1 Month at 7.32%.

What is the shareholding pattern of Concord Biotech Ltd?

Down Arrow

The shareholding pattern of Concord Biotech Ltd is as follows:
Promoters - 44.08 %
Institutions - 17.51 %
Public - 38.41 %

Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.